In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A*02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. This evidence concerns the gene GPC3 and hepatocellular carcinoma.